GLP-1 receptor agonists have moved rapidly from a niche diabetes therapy to a central pillar of metabolic treatment. For investors, this is no longer simply a clinical story. It is a structural shift in how obesity and related conditions are managed, funded and regulated.
Originally introduced to improve glycaemic control in type 2 diabetes, GLP-1RAs have gained prominence through demonstrated weight loss benefits during active treatment. That expansion has materially widened the addressable market. Demand has accelerated across both specialist and primary care settings, prompting regulators and health systems to respond with clearer prescribing frameworks and guidance on appropriate use.
The investment relevance lies in sustainability. While weight reduction during therapy has been consistent, outcomes following treatment discontinuation vary. Evidence suggests that weight regain can occur when therapy stops, raising questions around duration of treatment, reimbursement models and long-term adherence. This dynamic directly affects revenue visibility and pricing strategy. A therapy that requires extended use supports recurring revenue models but also invites payer scrutiny over cost-effectiveness.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
